OUR MISSION
To improve lower gastrointestinal health by preventing chemotherapy-induced toxicities and inflammation caused due to dietary, xenobiotics and genetic factors.
ABOUT US
Sanarentero, LLC is an early-stage drug development company that develops technologies to treat GI related diseases and disorders, and cancer chemotherapy-induced GI toxicities. It was founded and registered in the State of Texas in Oct 2019. Sanarentero is a University of Houston spin-off founded by Dr. Ming Hu and Dr. Rashim Singh to commercialize the technologies developed in Dr. Ming Hu’s lab at the College of Pharmacy.
OUR HISTORY
Sanarentero is a University of Houston spin-off founded by Dr. Ming Hu and Dr. Rashim Singh to commercialize the technologies developed in Dr. Ming Hu’s lab at the College of Pharmacy.
​
Dr. Ming Hu is an oral bioavailability expert and inventor with an expertise in manipulating the systemic and local bioavialabilities of xenobiotics by employing pharmacokinetic-based drug-designing and oral drug delivery approaches.
Dr. Singh has graduated from Dr. Hu’s lab and has an industrial experience in formulation technology and product development and post-doctoral research in drug-herb pharmacokinetic interactions.
COMPANY SUMMARY
Sanarentero, is an women-owned early-stage spin-out of the College of Pharmacy, University of Houston that aims to develop technologies to prevent and/or treat gut diseases and disorders, and cancer chemotherapy-induced gastrointestinal (GI) toxicities. Sanarentero was co-founded in Oct 2019 and registered in the State of Texas by Rashim Singh, PhD and Ming Hu, PhD with a vision to promote gut health by increasing its resilience against toxic drugs, dietary and environmental toxins. Sanrentero has research partnerships with several academic institutions in Texas for preclinical and clinical development of its research technologies, such as University of Houston, University of North Texas, Texas Southern University and Baylor College of Medicine. Based on our innovative research, we aim to protect the gut against toxic chemicals using naturally occurring herbs and chemicals or bioengineered probiotics that can enhance the detoxification ability of the lower intestine while protecting the gut microbiome against dysbiosis. Sanarentero has an excellent scientific team and clinical and business advisors for product development of its key technologies.
MANAGEMENT TEAM
Rashim Singh
Ph.D.
Rashim Singh, Co-founder and President of Sanarentero, is a female business owner and scientist-entrepreneur with 20+ years of multidisciplinary academic research and industrial experience in areas of drug disposition, drug-herb pharmacokinetic, drug-gut microbiome interactions, formulation, and product development. She is also employed at Sanarentero as the Principal Investigator of NIH-funded technologies currently under development.
Ming Hu
Ph.D.
Professor Ming Hu, Co-founder, Chief scientific Officer, and interim-CEO of Sanarentero, is an oral bioavailability expert and inventor with an expertise in manipulating the systemic and local bioavailabilities of xenobiotics by employing pharmacokinetic-based drug-designing and oral targeted drug delivery approaches. Dr. Hu also co-founded Allbright Pharmaceuticals; a start-up focused on developing patient-friendly potent formulations of herbal chemopreventive agents. Dr. Hu was also active in forming a contract research organization focused on drug metabolism, absorption, and bioanalysis.
BUSINESS CONSULTANTS
Srinivas Rao Chadaram
Ph.D., MBA
Dr. Srinivas Rao Chandram, business consultant with Sanarentero, is an entrepreneur CEO and co-founded an early-stage startup Aura Life in North Carolina to develop natural and organic ingredients-based COCOwipes for personal wellness. He has extensive experience in consumer interviews, market research, prototype testing for finalizing product concepts and offerings, developed products from concept to launch, product development cycles and e-commerce for market launch. Aura Life was accepted into GroundworkLabs, an incubator funded by NC IDEA and the HOTTovation program by Morrisville Innovation Foundation.
​
Dr. Chadaram currently manages a $10M portfolio of products for Fast & affordable genotyping by sequencing (GBS) solutions for Breeding in plants, animals, and aquaculture at Thermo Fisher Scientific. In the past, he has successfully commercialized and launched a Digital Microfluidics based platform for screening and diagnosis of Rare Diseases in newborns and a sample-prep platform for next-generation sequencing, for the start-up Advanced Liquid Logic, North Carolina, subsequently acquired by Illumina. He secured $10 million in grant funding, enabling product development, launch, and delivery for pilot testing despite stringent time and budget constraints. Additionally, he contributed to $500K annual revenue within the first year of the product by forging commercial contracts with Illinois and Missouri state public health programs, and research institutions including the Mayo Clinic, CDC, and NIHD-Japan.